FindTrial
Sign In

Assessment of pain and side effects between industrialized ointment with Lidocaine and manipulated Lidocaine ointment with Tetracaine for Hair Removal with Laser LightSheer®

Antalgic and adverse effects of the industrialized topical formulation of Lidocaine 4 compared to the manipulated formulation of Lidocaine 23 associated with Tetracaine 7 in patients referred for Laser Hair Removal Lightsheer®

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-373nm7
Enrollment
Unknown
Registered
2020-09-22
Start date
2012-05-11
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Seventy-seven patients participated in the study, with each patient being able to perform more than one procedure, resulting in a total of 256 procedures. Sixty minutes before the laser procedure, the
Drug
Procedure/surgery
E07.632.490

Sponsors

Clínica Dermatológica Dra Luciena Ortigosa
Lead Sponsor
Clínica Dermatológica Dra Luciena Ortigosa
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients with a desire for epilation; Patients with pigmented hair in axilla, face, legs or groin; Both sexes; Age between 12 and 90 years

Exclusion criteria

Exclusion criteria: Patients with a history of allergic reaction to lidocaine or tetracaine; Patients with keloid; Sun exposure in the four weeks prior to the laser procedure

Design outcomes

Primary

MeasureTime frame
To evaluate topical anesthetic with greater antialgic effects using the Wilcoxon's non parametric test. P-values lower than 0.05 were considered as statistically significant.—

Secondary

MeasureTime frame
Secondary outcomes were not expected—

Countries

Brazil

Contacts

Public ContactYara Martins Ortigosa Leonardo

Clínica Dermatológica Dra Luciena Ortigosa

yara_mot@hotmail.com+55011998501338

Outcome results

None listed

Source: REBEC (via WHO ICTRP)